A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer

Hiroko Shimada; Yuta Sato; Takashi Sasaki; Aki Shimozawa; Kent Imaizumi; Tomoko Shindo; Sachiyo Miyao; Kosuke Kiyama; Takahiro Kondo; Shinsuke Shibata; Seiji Ishii; Junro Kuromitsu; Hirofumi Aoyagi; Daisuke Ito; Hideyuki Okano

doi:10.1016/j.crmeth.2022.100289

A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer

Hiroko Shimada, Yuta Sato, Takashi Sasaki, Aki Shimozawa, Kent Imaizumi, Tomoko Shindo, Sachiyo Miyao, Kosuke Kiyama, Takahiro Kondo, Shinsuke Shibata, Seiji Ishii, Junro Kuromitsu, Hirofumi Aoyagi, Daisuke Ito, Hideyuki Okano

研究成果: Article › 査読

7 被引用数 (Scopus)

抄録

It is known that the human cellular models of Alzheimer's disease (AD) and tauopathy can only recapitulate the very early stage of the disease. To overcome these limitations, we developed a technology to make forebrain organoids (FBOs) from feeder-free induced pluripotent stem cells (iPSC)s by regulating a FGF2 concentration and applied this method to generate FBOs from patients with familial AD (fAD FBOs). The obtained fAD FBOs recapitulated the amyloid-β pathology and increased tau phosphorylation but not tau aggregates. To fully induce the tau pathology, FBOs were injected with adeno-associated virus (AAV)-expressing P301L mutant tau. In these Tau-P301L FBOs, tau fibrils were observed in the neuronal cell body and neurites with immunoelectron microscopy, in addition to the sarkosyl-insoluble and thioflavin S-positive phospho-tau aggregates. Collectively, this model can be used as a platform for investigating pathogenetic mechanisms and evaluation of target molecules for drug discovery for tauopathy.

本文言語	English
論文番号	100289
ジャーナル	Cell Reports Methods
巻	2
号	9
DOI	https://doi.org/10.1016/j.crmeth.2022.100289
出版ステータス	Published - 2022 9月 19

ASJC Scopus subject areas

バイオテクノロジー
生化学
生化学、遺伝学、分子生物学（その他）
遺伝学
放射線学、核医学およびイメージング
コンピュータサイエンスの応用

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.crmeth.2022.100289

他のファイルとリンク

引用スタイル

Shimada, H., Sato, Y., Sasaki, T., Shimozawa, A., Imaizumi, K., Shindo, T., Miyao, S., Kiyama, K., Kondo, T., Shibata, S., Ishii, S., Kuromitsu, J., Aoyagi, H., Ito, D., & Okano, H. (2022). A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer. Cell Reports Methods, 2(9), 記事 100289. https://doi.org/10.1016/j.crmeth.2022.100289

Shimada, H, Sato, Y, Sasaki, T, Shimozawa, A, Imaizumi, K, Shindo, T, Miyao, S, Kiyama, K, Kondo, T, Shibata, S, Ishii, S, Kuromitsu, J, Aoyagi, H, Ito, D & Okano, H 2022, 'A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer', Cell Reports Methods, vol. 2, no. 9, 100289. https://doi.org/10.1016/j.crmeth.2022.100289

@article{186e91f242b7438c8282b7fc41f964ca,

title = "A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer",

abstract = "It is known that the human cellular models of Alzheimer's disease (AD) and tauopathy can only recapitulate the very early stage of the disease. To overcome these limitations, we developed a technology to make forebrain organoids (FBOs) from feeder-free induced pluripotent stem cells (iPSC)s by regulating a FGF2 concentration and applied this method to generate FBOs from patients with familial AD (fAD FBOs). The obtained fAD FBOs recapitulated the amyloid-β pathology and increased tau phosphorylation but not tau aggregates. To fully induce the tau pathology, FBOs were injected with adeno-associated virus (AAV)-expressing P301L mutant tau. In these Tau-P301L FBOs, tau fibrils were observed in the neuronal cell body and neurites with immunoelectron microscopy, in addition to the sarkosyl-insoluble and thioflavin S-positive phospho-tau aggregates. Collectively, this model can be used as a platform for investigating pathogenetic mechanisms and evaluation of target molecules for drug discovery for tauopathy.",

keywords = "AAV, Alzheimer's disease, FGF2, brain organoids, feeder-free iPSCs, tau, tauopathy",

author = "Hiroko Shimada and Yuta Sato and Takashi Sasaki and Aki Shimozawa and Kent Imaizumi and Tomoko Shindo and Sachiyo Miyao and Kosuke Kiyama and Takahiro Kondo and Shinsuke Shibata and Seiji Ishii and Junro Kuromitsu and Hirofumi Aoyagi and Daisuke Ito and Hideyuki Okano",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = sep,

day = "19",

doi = "10.1016/j.crmeth.2022.100289",

language = "English",

volume = "2",

journal = "Cell Reports Methods",

issn = "2667-2375",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer

AU - Shimada, Hiroko

AU - Sato, Yuta

AU - Sasaki, Takashi

AU - Shimozawa, Aki

AU - Imaizumi, Kent

AU - Shindo, Tomoko

AU - Miyao, Sachiyo

AU - Kiyama, Kosuke

AU - Kondo, Takahiro

AU - Shibata, Shinsuke

AU - Ishii, Seiji

AU - Kuromitsu, Junro

AU - Aoyagi, Hirofumi

AU - Ito, Daisuke

AU - Okano, Hideyuki

PY - 2022/9/19

Y1 - 2022/9/19

N2 - It is known that the human cellular models of Alzheimer's disease (AD) and tauopathy can only recapitulate the very early stage of the disease. To overcome these limitations, we developed a technology to make forebrain organoids (FBOs) from feeder-free induced pluripotent stem cells (iPSC)s by regulating a FGF2 concentration and applied this method to generate FBOs from patients with familial AD (fAD FBOs). The obtained fAD FBOs recapitulated the amyloid-β pathology and increased tau phosphorylation but not tau aggregates. To fully induce the tau pathology, FBOs were injected with adeno-associated virus (AAV)-expressing P301L mutant tau. In these Tau-P301L FBOs, tau fibrils were observed in the neuronal cell body and neurites with immunoelectron microscopy, in addition to the sarkosyl-insoluble and thioflavin S-positive phospho-tau aggregates. Collectively, this model can be used as a platform for investigating pathogenetic mechanisms and evaluation of target molecules for drug discovery for tauopathy.

AB - It is known that the human cellular models of Alzheimer's disease (AD) and tauopathy can only recapitulate the very early stage of the disease. To overcome these limitations, we developed a technology to make forebrain organoids (FBOs) from feeder-free induced pluripotent stem cells (iPSC)s by regulating a FGF2 concentration and applied this method to generate FBOs from patients with familial AD (fAD FBOs). The obtained fAD FBOs recapitulated the amyloid-β pathology and increased tau phosphorylation but not tau aggregates. To fully induce the tau pathology, FBOs were injected with adeno-associated virus (AAV)-expressing P301L mutant tau. In these Tau-P301L FBOs, tau fibrils were observed in the neuronal cell body and neurites with immunoelectron microscopy, in addition to the sarkosyl-insoluble and thioflavin S-positive phospho-tau aggregates. Collectively, this model can be used as a platform for investigating pathogenetic mechanisms and evaluation of target molecules for drug discovery for tauopathy.

KW - AAV

KW - Alzheimer's disease

KW - FGF2

KW - brain organoids

KW - feeder-free iPSCs

KW - tau

KW - tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85138116349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138116349&partnerID=8YFLogxK

U2 - 10.1016/j.crmeth.2022.100289

DO - 10.1016/j.crmeth.2022.100289

M3 - Article

C2 - 36160042

AN - SCOPUS:85138116349

SN - 2667-2375

VL - 2

JO - Cell Reports Methods

JF - Cell Reports Methods

IS - 9

M1 - 100289

ER -

A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル